Triple therapy improves chronic rhinosinusitis outcomes in cystic fibrosis

Patients with cystic fibrosis had improved chronic rhinosinusitis outcomes after 1 year of elexacaftor/tezacaftor/ivacaftor therapy, according to results published in JAMA Otolaryngology-Head & Neck Surgery.
“During this study period (1 year), none of the patients with cystic fibrosis (CF) required sinus surgery, intravenous antibiotic therapy or hospitalization for worsening sinus disease,” Shahid Sheikh, MD, professor of pediatrics at The Ohio State University College of Medicine, told Healio. “This gives confidence to clinicians that with this therapy CF-related sinus

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.